Cargando…

Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays

INTRODUCTION: The role of the human immune system in pathologic responses to chemicals including nanomaterials was identified as a gap in current hazard assessments. However, the complexity of the human immune system as well as interspecies variations make the development of predictive toxicity test...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipsa, Dorelia, Ruiz Moreno, Ana, Desmet, Cloé, Bianchi, Ivana, Geiss, Otmar, Colpo, Pascal, Bremer-Hoffmann, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930575/
https://www.ncbi.nlm.nih.gov/pubmed/36816333
http://dx.doi.org/10.2147/IJN.S384184
_version_ 1784889068211929088
author Lipsa, Dorelia
Ruiz Moreno, Ana
Desmet, Cloé
Bianchi, Ivana
Geiss, Otmar
Colpo, Pascal
Bremer-Hoffmann, Susanne
author_facet Lipsa, Dorelia
Ruiz Moreno, Ana
Desmet, Cloé
Bianchi, Ivana
Geiss, Otmar
Colpo, Pascal
Bremer-Hoffmann, Susanne
author_sort Lipsa, Dorelia
collection PubMed
description INTRODUCTION: The role of the human immune system in pathologic responses to chemicals including nanomaterials was identified as a gap in current hazard assessments. However, the complexity of the human immune system as well as interspecies variations make the development of predictive toxicity tests challenging. In the present study, we have analysed to what extent fluctuations of the complement system of different individuals will have an impact on the standardisation of immunological tests. METHODS: We treated commercially available pooled sera (PS) from healthy males, individual sera from healthy donors and from patients suffering from cancer, immunodeficiency and allergies with small molecules and liposomes. Changes of iC3b protein levels measured in enzyme-linked immunosorbent assays served as biomarker for complement activation. RESULTS: The level of complement activation in PS differed significantly from responses of individual donors (p < 0.01). Only seven out of 32 investigated sera from healthy donors responded similarly to the pooled serum. This variability was even more remarkable when investigating the effect of liposomes on the complement activation in sera from donors with pre-existing pathologies. Neither the 26 sera of donors with allergies nor sera of 16 donors with immunodeficiency responded similar to the PS of healthy donors. Allergy sufferers showed an increase in iC3b levels of 4.16-fold changes when compared to PS treated with liposomes. DISCUSSION: Our studies demonstrate that the use of pooled serum can lead to an over- or under-estimation of immunological response in particular for individuals with pre-existing pathologies. This is of high relevance when developing medical products based on nanomaterials and asks for a review of the current practice to use PS from healthy donors for the prediction of immunological effects of drugs in patients. A better understanding of individual toxicological responses to xenobiotics should be an essential part in safety assessments.
format Online
Article
Text
id pubmed-9930575
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-99305752023-02-16 Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays Lipsa, Dorelia Ruiz Moreno, Ana Desmet, Cloé Bianchi, Ivana Geiss, Otmar Colpo, Pascal Bremer-Hoffmann, Susanne Int J Nanomedicine Original Research INTRODUCTION: The role of the human immune system in pathologic responses to chemicals including nanomaterials was identified as a gap in current hazard assessments. However, the complexity of the human immune system as well as interspecies variations make the development of predictive toxicity tests challenging. In the present study, we have analysed to what extent fluctuations of the complement system of different individuals will have an impact on the standardisation of immunological tests. METHODS: We treated commercially available pooled sera (PS) from healthy males, individual sera from healthy donors and from patients suffering from cancer, immunodeficiency and allergies with small molecules and liposomes. Changes of iC3b protein levels measured in enzyme-linked immunosorbent assays served as biomarker for complement activation. RESULTS: The level of complement activation in PS differed significantly from responses of individual donors (p < 0.01). Only seven out of 32 investigated sera from healthy donors responded similarly to the pooled serum. This variability was even more remarkable when investigating the effect of liposomes on the complement activation in sera from donors with pre-existing pathologies. Neither the 26 sera of donors with allergies nor sera of 16 donors with immunodeficiency responded similar to the PS of healthy donors. Allergy sufferers showed an increase in iC3b levels of 4.16-fold changes when compared to PS treated with liposomes. DISCUSSION: Our studies demonstrate that the use of pooled serum can lead to an over- or under-estimation of immunological response in particular for individuals with pre-existing pathologies. This is of high relevance when developing medical products based on nanomaterials and asks for a review of the current practice to use PS from healthy donors for the prediction of immunological effects of drugs in patients. A better understanding of individual toxicological responses to xenobiotics should be an essential part in safety assessments. Dove 2023-02-11 /pmc/articles/PMC9930575/ /pubmed/36816333 http://dx.doi.org/10.2147/IJN.S384184 Text en © 2023 Lipsa et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lipsa, Dorelia
Ruiz Moreno, Ana
Desmet, Cloé
Bianchi, Ivana
Geiss, Otmar
Colpo, Pascal
Bremer-Hoffmann, Susanne
Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays
title Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays
title_full Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays
title_fullStr Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays
title_full_unstemmed Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays
title_short Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays
title_sort inter-individual variations: a challenge for the standardisation of complement activation assays
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930575/
https://www.ncbi.nlm.nih.gov/pubmed/36816333
http://dx.doi.org/10.2147/IJN.S384184
work_keys_str_mv AT lipsadorelia interindividualvariationsachallengeforthestandardisationofcomplementactivationassays
AT ruizmorenoana interindividualvariationsachallengeforthestandardisationofcomplementactivationassays
AT desmetcloe interindividualvariationsachallengeforthestandardisationofcomplementactivationassays
AT bianchiivana interindividualvariationsachallengeforthestandardisationofcomplementactivationassays
AT geissotmar interindividualvariationsachallengeforthestandardisationofcomplementactivationassays
AT colpopascal interindividualvariationsachallengeforthestandardisationofcomplementactivationassays
AT bremerhoffmannsusanne interindividualvariationsachallengeforthestandardisationofcomplementactivationassays